

**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions and listings of claims in the application:

- 1-21. (Cancelled).
22. (Currently Amended) An amine salt of a carbostyryl derivative comprising 2-(4-chlorobenzoylamino)-3-(2-quinolon-4-yl)propionic acid and an amine selected from the group consisting of L-arginine, L-lysine, ethylenediamine, tris(hydroxymethyl) aminomethane, monoethanolamine, diethanolamine[[.]], diisopropanolamine, and meglumine.
23. (Previously Presented) A pharmaceutical formulation comprising the amine salt of the carbostyryl derivative according to claim 22 as the active ingredient.
24. (Previously Presented) A pharmaceutical formulation which is prepared in the form of an aqueous solution by adding an aqueous solvent when used, comprising 2-(4-chlorobenzoylamino)-3-(2-quinolon-4-yl)propionic acid and an amine selected from the group consisting of L-arginine, L-lysine, ethylenediamine, tris(hydroxymethyl) aminomethane, monoethanolamine, diethanolamine, diisopropanolamine and, meglumine.
25. (New) The amine salt of the carbostyryl derivative according to claim 22, wherein said amine is L-arginine.
26. (New) The amine salt of the carbostyryl derivative according to claim 22, wherein said amine is L-lysine.
27. (New) The amine salt of the carbostyryl derivative according to claim 22, wherein said amine is ethylenediamine.

28. (New) The amine salt of the carbostyryl derivative according to claim 22, wherein said amine is tris(hydroxymethyl) aminomethane.
29. (New) The amine salt of the carbostyryl derivative according to claim 22, wherein said amine is monoethanolamine.
30. (New) The amine salt of the carbostyryl derivative according to claim 22, wherein said amine is diethanolamine.
31. (New) The amine salt of the carbostyryl derivative according to claim 22, wherein said amine is diisopropanolamine.
32. (New) The amine salt of the carbostyryl derivative according to claim 22, wherein said amine is meglumine.
33. (New) The pharmaceutical formulation to be prepared in a preparation when used according to claim 24, wherein said amine is L-arginine.
34. (New) The pharmaceutical formulation to be prepared in a preparation when used according to claim 24, wherein said amine is L-lysine.
35. (New) The pharmaceutical formulation to be prepared in a preparation when used according to claim 24, wherein said amine is ethylenediamine.
36. (New) The pharmaceutical formulation to be prepared in a preparation when used according to claim 24, wherein said amine is tris(hydroxymethyl) aminomethane.
37. (New) The pharmaceutical formulation to be prepared in a preparation when used according to claim 24, wherein said amine is monoethanolamine.
38. (New) The pharmaceutical formulation to be prepared in a preparation when used according to claim 24, wherein said amine is diethanolamine.

39. (New) The pharmaceutical formulation to be prepared in a preparation when used according to claim 24, wherein said amine is diisopropanolamine.

40. (New) The pharmaceutical formulation to be prepared in a preparation when used according to claim 24, wherein said amine is meglumine.